Claim Credits Now View Presentations
ACTIVITY OVERVIEW
This symposium will describe recent advances in our understanding of the pathophysiology of myelodysplastic syndromes and related myeloid neoplasms, and how these advances are being translated into more effective treatments for these patients.
TARGET AUDIENCE
This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.
LEARNING OBJECTIVES
Upon completion of the educational activity, participants should be able to:
FACULTY
Director, Sylvester Comprehensive Cancer Center
Professor of Medicine, Biochemistry & Molecular Biology
University of Miami Miller School of Medicine
Miami, Florida
Professor of Hematology
Department of Molecular Medicine, University of Pavia
Chief, Division of Hematology
Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo
Pavia, Italy
Director, Department of Medicine
Tel-Aviv Sourasky Medical Center
Tel-Aviv, Israel
Memorial Sloan Kettering Cancer Center
New York City, New York
Heisenberg Chair for Molecular Therapies in Hematology
Hannover Medical School
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation
Hannover, Germany
Head of Department
Professor of Haemato Oncology in Haematological Medicine
King’s College London & King’s College Hospital
London, United Kingdom
Professor of Medicine
Director of Hematology Research
Director, Hematology Early Therapeutics Program
Vanderbilt-Ingram Cancer Center
Department of Medicine, Division of Hematology & Oncology
Nashville, Tennessee, United States
Professor
Washington University School of Medicine in St. Louis
Department of Medicine, Oncology Division
St. Louis, Missouri
AGENDA
| Friday, November 30, 2018 7:00 – 7:30 am Breakfast 7:30 – 11:00 am Symposium |
|
| SCIENTIFIC PROGRAM Co-Chairs: Mario Cazzola, MD (Pavia, Italy) Moshe Mittelman, MD (Tel Aviv, Israel) |
|
| 7:30 – 7:35 am | Welcome and Overview – About the MDS Foundation, Inc. Mario Cazzola, MD University of Pavia Pavia, Italy |
| 7:35 – 7:40 am | Program Overview and Objectives Moshe Mittelman, MD Tel-Aviv Sourasky Medical Center Tel-Aviv, Israel |
| 7:40 – 8:15 am | Update of Mutational Impact on Diagnostic and Prognostic Evaluation of MDS Elsa Bernard, PhD Memorial Sloan Kettering Cancer Center New York City, New York, United States |
| 8:15 – 8:50 am | High-Risk MDS and AML: One or Two Diseases? Michael Heuser, MD Hannover Medical School Hannover, Germany |
| 8:50 – 9:25 am | Myeloid Malignancies Associated with Spliceosome Mutations Matthew Walter, MD Washington University School of Medicine in St. Louis St. Louis, Missouri, United States |
| 9:25 – 10:00 am | Epigenetic Therapies: What’s Next? Michael Savona, MD Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States |
| 10:00 – 10:35 am | Recent Advances in Allogeneic Transplantation and Prospects for Cellular Therapy Ghulam Mufti, DM, FRCP, FRCPath King’s College London & King’s College Hospital London, United Kingdom |
| 10:35 – 11:00am | Questions/Answers/Discussion |
CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s attendance, participation in the pre/post-test and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at https://www.mds-foundation.org/learning-center/mds-2018/. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CME/CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.
ACCREDITATION
CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare
PHYSICIANS
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and the Myelodysplastic Syndromes Foundation, Inc. (MDSF). AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PHYSICIAN ASSISTANTS
NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
PHARMACY
AKH, Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AKH, Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 3.5 contact hour(s) (0.35 CEUs). UAN 0077-9999-18-025-L04-P.
NURSING
AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity is awarded 3.5 Contact Hours.
Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and the Myelodysplastic Syndromes Foundation, Inc. (MDSF).
COMMERCIAL SUPPORT
This activity is supported by an educational grant from Celgene Corporation, Jazz Pharmaceuticals, Inc., Onconova Therapeutics, Inc. and Takeda Oncology.
AMERICANS WITH DISABILITIES ACT
AKH Inc, Advancing Knowledge in Healthcare fully intends to comply with the legal requirements of the Americans with Disabilities Act. If you need assistance, please notify AKH at 904-683-8843 at least two weeks prior to the activity.
*Activity and faculty subject to change
